建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
(Supplementary Explanation) Announcement of the Company's board of directors' resolution on the change of the cash capital increase plan for 2020
Announcement of the Company's board of directors' resolution on the change of the cash capital increase plan for 2020
The Company's 2024Q3 consolidated financial statements have been approved by the Board of Directors
Bonvadis topical cream received medical device marketing authorization approval for all indications in wounds for Saudi Arabia
Announcement of the date of the Company's board of directors meeting for the Thired Quarter of 2024 Consolidated Financial Reports
A US patent titled "Biomarkers for lung cancer stem cells" has been granted
Oneness Biotech Co., Ltd. receives a United States patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825.
Oneness has received medical device registration approval on Bonvadis Topical Cream for Egypt
Oneness announces the information about the investor's conference of 2024 Q3.
National Health Security Administration of China has not included Fespixon Cream in this year NRDL adjustment negotiation after the expert review.
Oneness & Microbio (Shanghai) host an international press conference to present the pan-COVID new drug, SNS812 Phase 2 clinical trial results and future prospects
SNS812 Phase 2 study demonstrated statistical significance in treating COVID-19 based on its safety, precision and broad-spectrum efficacy.
The post hoc analysis of the global novel drug, Fespixon (ON101), on hard-to-heal diabetic foot ulcers has been published in Advances in Wound Care
The Company's security trading have reached threshold of mandatory disclosure of financial information per TPEx requirements
Oneness Biotech Co., Ltd. receives a Japanese patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?